Company profile: Turnstone Biologics
1.1 - Company Overview
Company description
- Provider of clinical-stage cancer immunotherapies leveraging two complementary platforms: Selected TIL therapies and viral immunotherapy for solid tumors. Offerings include TIDAL-01 and TIDAL-02 Selected TILs, RIVAL-01 viral immunotherapy, and combination Selected TILs + Virus approaches to enhance TIL trafficking and infiltration.
Products and services
- TIDAL-01: Clinical-stage product employing tumor-reactive Selected TILs for melanoma, breast, and colorectal solid tumors, with precise selection and expansion of potent patient-derived T cells
- TIDAL-02: Next-generation Selected TIL therapy featuring enhanced manufacturing and improved TIL quality, architected to treat solid tumors via expansion of highly tumor-reactive patient-derived T cells
- RIVAL-01: SKV Vaccinia-based viral immunotherapy engineered to infect, replicate within, and lyse tumor cells, driving oncolytic and immune-mediated killing of tumors
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Turnstone Biologics
MinervaX
HQ: Denmark
Website
- Description: Provider of a biotechnology solution developing a novel vaccine against Group B Streptococcus (GBS) using a fusion protein shown to elicit protective immunity; offering the AlpN GBS Vaccine candidate designed for pregnant women and older adults to prevent GBS infections and likely protect against many clinically relevant GBS strains.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MinervaX company profile →
MBrace Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical oncology solutions, including MBRC-101, an antibody-drug conjugate targeting the EphA5 receptor for solid tumors such as breast and lung cancer; SPARTA, a proprietary platform to identify new cancer targets and accelerate ADC development; and a Phase 1/1b clinical trial of MBRC-101 evaluating safety, tolerability, and preliminary efficacy in advanced metastatic solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MBrace Therapeutics company profile →
Caelum Biosciences
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology developing treatments for rare and life-threatening diseases, with lead asset CAEL-101 (mAb 11-1F4), a novel antibody licensed from Columbia University in January 2017 for the treatment of amyloid light chain (AL) amyloidosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Caelum Biosciences company profile →
Lassen Therapeutics
HQ: United States
Website
- Description: Provider of antibody biotherapeutics, developing monoclonal antibodies including LASN01, which targets the IL-11 receptor to treat fibro-inflammatory diseases such as thyroid eye disease and idiopathic pulmonary fibrosis, and LASN500, which targets IL-18 binding protein to elevate IL-18 at the tumor site for cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lassen Therapeutics company profile →
Protein Sciences
HQ: United States
Website
- Description: Provider of vaccine and biopharmaceutical research and development for the prevention and treatment of a variety of diseases, leveraging proprietary BEVS protein expression technology to produce high-quality recombinant proteins quickly, reliably, and at low cost; founded in 1983 with over 30 years of experience creating vaccines and other protective medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protein Sciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Turnstone Biologics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Turnstone Biologics
2.2 - Growth funds investing in similar companies to Turnstone Biologics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Turnstone Biologics
4.2 - Public trading comparable groups for Turnstone Biologics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →